This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Roivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation in the eastern […]
Gradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).
AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a 21m Series A financing.
Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory diseases.
The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.
The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.
French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.
Evotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at developing novel immunooncological drugs
The 13th annual BIO-Europe Spring international partnering conference will be held in Vienna, Austria, for the first time, March 2527, 2019, at the Messe Wien Exhibition and Congress Center. The […]
A research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer.